AVEIR DR Dual Chamber Leadless Pacemaker System

The Leadless Advantage

Introducing the World's First Dual Chamber Leadless Pacemaker System¹

Brought to you only by Abbott, the AVEIR DR™ Dual Chamber Leadless Pacemaker (LP) System is a first-of-its-kind leadless pacing system that provides:

  • Beat-to-Beat Synchrony between both chambers.2,3
  • Upgradeability from single to dual chamber therapy.2
  • Long-Term Retrieval to remove hardware at end of service (EOS).2,4
  • Electrical Mapping Before Fixation to reduce repositioning.2,3

Our life-changing technology provides all the clinical benefits of traditional dual chamber pacemakers without the downsides. This means:

  • NO pocket- and lead-related complications (including infection, lead fracture, insulation problems, skin erosion and keloid formation).
  • NO visible scarring.
  • NO movement restrictions post-implantation.

Beat-to-Beat Synchrony2,3

AVEIR™ DR Leadless Pacemaker System is capable of pacing and sensing in both chambers through the combination of an atrial leadless pacemaker (AVEIR™ AR LP) and a ventricular leadless pacemaker (AVEIR™ VR LP).

Dual chamber, leadless synchronous pacing between the atrium and the ventricle is made possible with industry-first, proprietary i2i™ communication technology capable of providing true DDDR pacing for continuous, atrioventricular (AV) synchrony, regardless of patient posture.

More than 95%
Mean AV synchrony observed for multiple postures and gaits (including sitting, supine, left lateral recumbent, right lateral recumbent, standing, normal walking and fast walking).3

≥95% AV Synchrony Observed for Multiple Postures and Gaits3

Mean Atrioventricular Synchrony
Mean Atrioventricular Synchrony

Implant-to-Implant (i2i™) Technology2

i2i Communication

This novel technology features paired, co-implanted devices employing low-energy, subthreshold pulses between them using the conductive nature of the body’s blood pool and myocardial tissue.

High-frequency pulses are delivered concurrently with each locally paced or sensed event without impact on pacing or intrinsic sensing.

Upgradable System2

Patient therapy can be tailored by implanting an atrial or ventricular device alone, or both combined, for dual chamber support. The option to upgrade over time allows you to:

  • Meet your patients’ needs today
  • Adapt to common disease progression to meet your patients’ needs in the future
     

Option to Start with Ventricular Pacing

Treat patients for rare intermittent A-V block today.

Add Atrial Pacing Later

Treat those same patients by adding an atrial device if sick sinus syndrome develops later to provide DDDR therapy.

Achieve Dual Chamber Pacing

Now you have options to adapt to patient needs over time.

Long-term Retrieval2,4,5

This allows for the replacement of the atrial or ventricular device at end of service (EOS) without leaving hardware behind.

The AVEIR™ VR ventricular leadless pacemaker predicate device has a longterm retrieval success rate above 88% with helix fixation through 9 years regardless of implant duration.4

88%

Retrieval Success by Implant Duration4

Retrieval Success Chart

The specialty designed retrieval catheter provides added confidence and is supported by a step-by-step retrieval protocol.5 AVEIR™ devices have an active fixation design that uses a screw-in mechanism to enable both implantation and long-term retrieval of the atrial and ventricular devices.2

Mapping Prior to Fixation2,3

Electrical mapping prior to fixation is designed to help reduce the number of repositioning attempts in the atrium and ventricle. AVEIR™ Leadless Pacemakers can assess current of injury via Commanded EGM, initial pacing capture thresholds, sensing amplitudes, and impedance in both atrial and ventricular chambers.

of patients had successful VENTRICULAR IMPLANTS WITH 1 OR LESS REPOSITIONING ATTEMPTS.3

98%

of patients had successful ATRIAL IMPLANTS WITH 1 OR LESS REPOSITIONING ATTEMPTS.3

90%

Proven Clinical Evidence3


Across 300 attempted implants, the procedure was successful in 295 patients for a

Dual Chamber Procedure Success Rate3

98%

View safety and efficacy results observed at the three-month follow-up of the AVEIR™ DR i2i™ Study as cited in the New England Journal of Medicine.

Partnering With You to Personalize Care

From diagnosis through treatment and ongoing patient management, we're partnering with you. Be the first to receive new information regarding clinical studies, press releases and more. Sign up for updates on the launch of AVEIR™ DR Dual Chamber Leadless Pacemaker System.

Intended for U.S. residents only. Please review our privacy policy and terms & conditions.

 

References

  1. AVEIR™ DR FDA Approval.
  2. AVEIR™ Leadless Pacemakers and Delivery Catheter IFU, ARTEN600284235.
  3. Knops, Reinoud E., et al. "A Dual-Chamber Leadless Pacemaker." New England Journal of Medicine (2023). DOI: 10.1056/NEJMoa2300080
  4. Reddy, VY, et al. Worldwide Experience with Leadless Pacemaker Retrievals: A Worldwide Nanostim Experience out of 9y. Presented at: APHRS 2022; Nov 18-20, 2022; Singapore.
  5. AVEIR™ Retrieval Catheter IFU. ARTMT600174816.

MAT-2307559 v1.0